Literature DB >> 2472674

Major amputation for advanced malignant melanoma.

D P Jaques1, D G Coit, M F Brennan.   

Abstract

The Memorial Sloan-Kettering Cancer Center experience with major amputation for advanced malignant melanoma from 1965 to 1984 is reported. This is a retrospective review of 58 patients who underwent hemipelvectomy, disarticulation of the hip and above knee or forequarter amputation for advanced or recurrent malignant melanoma. Major amputation with curative intent was performed upon 43 patients. There were three deaths that occurred 30 days postoperatively (7 per cent). Intransit metastasis was one of the indications for amputation in 33 patients, and local control of disease was achieved in 30 of 43 patients. The median time to recurrence in those patients who did have a recurrence was 12 months (a range of 18 days to 16 years). Fifteen of 40 patients who survived the operation had no evidence of disease five years after undergoing a major amputation. Age, sex, primary site, stage of disease at diagnosis and amputation, disease-free interval and positive node status at any time during the course of the disease were not predictive of the outcome. Neurovascular involvement with melanoma and positive margins of resection predicted early failure. A palliative amputation for impending major vascular disruption or extensive, fungating disease was performed upon 15 patients. There was one death 30 days after the operation, and generally, hospitalization did not exceed 30 days. Median survival time was five months. All of the patients died of local or distant disease within 33 months of treatment. Local recurrence preceded death in nine of 15 patients.

Entities:  

Mesh:

Year:  1989        PMID: 2472674

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  12 in total

Review 1.  Palliative surgery for cancer pain.

Authors:  Laurence McCahill; Betty Ferrell
Journal:  West J Med       Date:  2002-03

2.  The role of radical amputations for extremity tumors: a single institution experience and review of the literature.

Authors:  Colin M Parsons; Jose M Pimiento; David Cheong; Suroosh S Marzban; Ricardo J Gonzalez; David Johnson; G Douglas Letson; Jonathan S Zager
Journal:  J Surg Oncol       Date:  2011-08-11       Impact factor: 3.454

3.  Patterns of failure following the excision of in-transit lesions in melanoma and the influence of excisional margins.

Authors:  Alexandra B Gonzalez; Christian L Baum; Jerry D Brewer; Christopher J Arpey; William S Harmsen; Vera J Suman; Svetomir N Markovic; James W Jakub
Journal:  J Surg Oncol       Date:  2018-08-16       Impact factor: 3.454

4.  Complications and outcome of external hemipelvectomy in the management of pelvic tumors.

Authors:  J P Apffelstaedt; D L Driscoll; J E Spellman; A F Velez; J F Gibbs; C P Karakousis
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

5.  Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector.

Authors:  Dennis Kobelt; Jutta Aumann; Manuel Schmidt; Burghardt Wittig; Iduna Fichtner; Diana Behrens; Margit Lemm; Greta Freundt; Peter M Schlag; Wolfgang Walther
Journal:  Mol Oncol       Date:  2014-01-18       Impact factor: 6.603

6.  Isolated limb infusion: Efficacy, toxicity and an evolution in the management of in-transit melanoma.

Authors:  Laura Chin-Lenn; Claire Temple-Oberle; J Gregory McKinnon
Journal:  Plast Surg (Oakv)       Date:  2015       Impact factor: 0.947

7.  Molecular clonality of in-transit melanoma metastasis.

Authors:  T Nakayama; B Taback; R Turner; D L Morton; D S Hoon
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 8.  Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Authors:  Dale Han; Georgia M Beasley; Douglas S Tyler; Jonathan S Zager
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-10-07       Impact factor: 4.481

9.  A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence.

Authors:  Joshua M Judge; Louis B Brill; Kelly T Smith; Donna H Deacon; James W Patterson; William W Grosh; Achim A Jungbluth; Sacha Gnjatic; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2013-05-12       Impact factor: 6.968

Review 10.  Management of in-transit melanoma of the extremity with isolated limb perfusion.

Authors:  Douglas L Fraker
Journal:  Curr Treat Options Oncol       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.